Key clinical point: Monitoring routine plasma levels of imatinib may help optimize treatment dosage, thereby enabling treatment individualization and improving clinical outcomes in patients with chronic myeloid leukemia (CML).
Major finding: Only 39.3% patients showed minimum imatinib plasma concentrations measured at steady state (Cssmin) within therapeutic range (750-1500 ng/mL). Optimal molecular response was achieved by 100% vs. 50% of patients with Cssmin ≥750 ng/mL vs. <750 ng/mL ( P = .0004). The rate of toxicity was higher in patients with Cssmin >1500 ng/mL vs. ≤1500 ng/mL (36.4% vs. 5.9%; P = .039).
Study details: This cross-sectional study included 28 patients with CML treated with imatinib for >1 month.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Del Rosario García B et al. J Oncol Pharm Pract. 2021 (Oct 18). Doi: 10.1177/10781552211052535.